Business Wire

Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine ...
Business Wire

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2 nd JAK Inhibitors Drug Development Summit

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine ...
Seeking Alpha

Opko hits enrollment target in late stage study of hGH-CTP in growth hormone deficient adults

Opko Health (OPK +0.2%) completes enrollment in the pivotal Phase 3 clinical trial assessing its long-acting human growth hormone (hGH-CTP) in growth hormone deficient adults. The treatment period in ...